|
Adenoma
|
0.330 |
Biomarker
|
group |
CTD_human |
Three SNPs located in the 3' region of SEPP1, which is overlapping with the promoter region of an antisense transcript, were significantly associated with adenoma risk: homozygotes at two SEPP1 loci (31,174 bp 3' of STP A>G and 43,881 bp 3' of STP G>A) were associated with increased adenoma risk [odds ratio (OR), 1.48; 95% confidence interval (95% CI), 1.00-2.19 and OR, 1.53; 95% CI, 1.05-2.22, respectively] and the variant SEPP1 44,321 bp 3' of STP C>T was associated with a reduced adenoma risk (CT versus CC OR, 0.85; 95% CI, 0.63-1.15).
|
18483336 |
2008 |
|
Adenoma
|
0.330 |
GeneticVariation
|
group |
BEFREE |
Three SNPs located in the 3' region of SEPP1, which is overlapping with the promoter region of an antisense transcript, were significantly associated with adenoma risk: homozygotes at two SEPP1 loci (31,174 bp 3' of STP A>G and 43,881 bp 3' of STP G>A) were associated with increased adenoma risk [odds ratio (OR), 1.48; 95% confidence interval (95% CI), 1.00-2.19 and OR, 1.53; 95% CI, 1.05-2.22, respectively] and the variant SEPP1 44,321 bp 3' of STP C>T was associated with a reduced adenoma risk (CT versus CC OR, 0.85; 95% CI, 0.63-1.15).
|
18483336 |
2008 |
|
Adenoma
|
0.330 |
GeneticVariation
|
group |
LHGDN |
Three SNPs located in the 3' region of SEPP1, which is overlapping with the promoter region of an antisense transcript, were significantly associated with adenoma risk: homozygotes at two SEPP1 loci (31,174 bp 3' of STP A>G and 43,881 bp 3' of STP G>A) were associated with increased adenoma risk [odds ratio (OR), 1.48; 95% confidence interval (95% CI), 1.00-2.19 and OR, 1.53; 95% CI, 1.05-2.22, respectively] and the variant SEPP1 44,321 bp 3' of STP C>T was associated with a reduced adenoma risk (CT versus CC OR, 0.85; 95% CI, 0.63-1.15).
|
18483336 |
2008 |
|
Adenoma
|
0.330 |
AlteredExpression
|
group |
BEFREE |
Previously, we have demonstrated dramatically reduced SeP expression in human colon adenomas.
|
12173025 |
2002 |
|
Adenoma
|
0.330 |
Biomarker
|
group |
BEFREE |
It remains to be shown whether upregulation of gastrointestinal glutathione peroxidase in adenomas represents a compensatory mechanism to reduce susceptibility for oxidative damage resulting from the loss of selenoprotein P.
|
10965527 |
2000 |
|
Prostatic Neoplasms
|
0.320 |
AlteredExpression
|
group |
BEFREE |
Quantitative real-time reverse transcription-PCR for Selenoprotein-P demonstrated a similar down-regulation of the transcript of this gene in a subset of human prostate tumors, mouse tumors, and prostate carcinoma cell lines.
|
12235003 |
2002 |
|
Prostatic Neoplasms
|
0.320 |
Biomarker
|
group |
CTD_human |
Quantitative real-time reverse transcription-PCR for Selenoprotein-P demonstrated a similar down-regulation of the transcript of this gene in a subset of human prostate tumors, mouse tumors, and prostate carcinoma cell lines.
|
12235003 |
2002 |
|
Prostatic Neoplasms
|
0.320 |
Biomarker
|
group |
BEFREE |
In a low-selenium population, SOD2-Ala16+ men homozygous for SEPP1-Ala234 are at an increased risk of prostate cancer/aggressive prostate cancer especially if ever-smokers, because they are likely to produce more mitochondrial H(2)O(2) that they cannot remove, thereby promoting prostate tumor cell proliferation and migration.
|
19074884 |
2008 |
|
Neurodegenerative Disorders
|
0.310 |
Biomarker
|
group |
CTD_human |
Pharmacogenomic profiling of an oxidative stress-mediated spongiform encephalopathy.
|
15964507 |
2005 |
|
Neurodegenerative Disorders
|
0.310 |
Biomarker
|
group |
BEFREE |
Our findings demonstrate that SelP protects neuronal cells from Abeta-induced toxicity, suggesting a neuroprotective role for SelP in preventing neurodegenerative disorders.
|
20521393 |
2010 |
|
Carcinoma
|
0.300 |
Biomarker
|
group |
CTD_human |
cDNA microarray profiling of rat mammary gland carcinomas induced by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and 7,12-dimethylbenz[a]anthracene.
|
12376462 |
2002 |
|
Carcinoma
|
0.300 |
Biomarker
|
group |
CTD_human |
Global gene expression profiling of chemically induced rat mammary gland carcinomas and adenomas.
|
16316942 |
2005 |
|
Colorectal Neoplasms
|
0.300 |
Biomarker
|
group |
CTD_human |
Variation in the selenoenzyme genes and risk of advanced distal colorectal adenoma.
|
18483336 |
2008 |
|
Lung Neoplasms
|
0.300 |
Biomarker
|
group |
CTD_human |
Expression of selenoprotein-coding genes SEPP1, SEP15 and hGPX1 in non-small cell lung cancer.
|
19058871 |
2009 |
|
nervous system disorder
|
0.300 |
Biomarker
|
group |
CTD_human |
Hepatic selenoprotein P (SePP) expression restores selenium transport and prevents infertility and motor-incoordination in Sepp-knockout mice.
|
17961124 |
2008 |
|
nervous system disorder
|
0.300 |
Biomarker
|
group |
CTD_human |
Neurological dysfunction occurs in mice with targeted deletion of the selenoprotein P gene.
|
14704310 |
2004 |
|
Degenerative Diseases, Central Nervous System
|
0.300 |
Biomarker
|
group |
CTD_human |
Pharmacogenomic profiling of an oxidative stress-mediated spongiform encephalopathy.
|
15964507 |
2005 |
|
Degenerative Diseases, Spinal Cord
|
0.300 |
Biomarker
|
group |
CTD_human |
Pharmacogenomic profiling of an oxidative stress-mediated spongiform encephalopathy.
|
15964507 |
2005 |
|
Cardiovascular Diseases
|
0.040 |
Biomarker
|
group |
BEFREE |
We conclude that the 20% with lowest SELENOP concentrations in a North European population without history of cardiovascular disease have markedly increased risk of cardiovascular morbidity and mortality, and preventive selenium supplementation studies stratified for these subjects are warranted.
|
31404994 |
2019 |
|
Cardiovascular Diseases
|
0.040 |
Biomarker
|
group |
BEFREE |
Because SeP confers protection against disease by reducing chronic oxidative stress, the present study aimed to assess the level of SeP in the serum of patients with metabolic syndrome (MetS) with a history of cardiovascular disease (CVD).
|
28190280 |
2017 |
|
Cardiovascular Diseases
|
0.040 |
AlteredExpression
|
group |
BEFREE |
This study aimed to determine the risk of CVD in NAFLD patients and the association of serum SelP levels with this NAFLD related CVD risk.
|
28760353 |
2017 |
|
Cardiovascular Diseases
|
0.040 |
AlteredExpression
|
group |
BEFREE |
Effect of single nucleotide polymorphisms in SEPS1 and SEPP1 on expression in the protein level in metabolic syndrome in subjects with cardiovascular disease.
|
31542866 |
2019 |
|
Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
Alterations in gene expression profiles during prostate cancer progression: functional correlations to tumorigenicity and down-regulation of selenoprotein-P in mouse and human tumors.
|
12235003 |
2002 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
The results shown that combined SEP and αPD-L1 presented significant synergistic antitumor effects, increased the frequency of CD8<sup>+</sup> and CD4<sup>+</sup> T cells in spleen and tumor, cytotoxic activity of CTL in spleen, and IL-2 and IFN-γ levels in splenocytes and tumor.
|
29317734 |
2018 |
|
Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
Selenium may affect prostate cancer risk via its plasma carrier selenoprotein P which shows dramatically reduced expression in prostate cancer tumors and cell lines.
|
19074884 |
2008 |